At study completion , D-002 reduced total WOMAC ( 65.4 % ) , pain ( 54.9 % ) , joint stiffness ( 76.8 % ) , and physical function ( 66.9 % ) WOMAC scores , and the VAS score ( 46.8 % ) versus placebo .